0001794785-20-000003.txt : 20200124 0001794785-20-000003.hdr.sgml : 20200124 20200124132829 ACCESSION NUMBER: 0001794785-20-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200124 DATE AS OF CHANGE: 20200124 EFFECTIVENESS DATE: 20200124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AETHLON MEDICAL INC CENTRAL INDEX KEY: 0000882291 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 133632859 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-358888 FILM NUMBER: 20544662 BUSINESS ADDRESS: STREET 1: 9635 GRANITE RIDGE DRIVE, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92123 BUSINESS PHONE: 858-459-7800 MAIL ADDRESS: STREET 1: 9635 GRANITE RIDGE DRIVE, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92123 FORMER COMPANY: FORMER CONFORMED NAME: BISHOP EQUITIES INC DATE OF NAME CHANGE: 19930602 D 1 primary_doc.xml X0708 D LIVE 0000882291 AETHLON MEDICAL INC 9635 GRANITE RIDGE DRIVE, SUITE 100 SAN DIEGO CA CALIFORNIA 92123 858-459-7800 NEVADA BISHOP EQUITIES INC Corporation true TIMOTHY C. RODELL 9635 GRANITE RIDGE DRIVE, SUITE 100 SAN DIEGO CA CALIFORNIA 92123 Executive Officer Director SABRINA MARTUCCI JOHNSON 9635 GRANITE RIDGE DRIVE, SUITE 100 SAN DIEGO CA CALIFORNIA 92123 Director EDWARD G. BROENNIMAN 9635 GRANITE RIDGE DRIVE, SUITE 100 SAN DIEGO CA CALIFORNIA 92123 Director CHARLES J. FISHER 9635 GRANITE RIDGE DRIVE, SUITE 100 SAN DIEGO CA CALIFORNIA 92123 Director CHETAN S. SHAH 9635 GRANITE RIDGE DRIVE, SUITE 100 SAN DIEGO CA CALIFORNIA 92123 Director JAMES B. FRAKES 9635 GRANITE RIDGE DRIVE, SUITE 100 SAN DIEGO CA CALIFORNIA 92123 Executive Officer GUY CIPRIANI 9635 GRANITE RIDGE DRIVE, SUITE 100 SAN DIEGO CA CALIFORNIA 92123 Director Biotechnology Decline to Disclose 06b false 2020-01-22 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue, 4th Floor New York NY NEW YORK 10022 IL ILLINOIS NY NEW YORK VT VERMONT false 2733797 2733797 0 Represents amounts receivable upon exercise of warrants to purchase common stock; such warrants have not yet been exercised. false 7 226245 0 In addition, the placement agent was reimbursed $82,900 for expenses relating to the offering and received $37,707.56 for management fees. 0 false AETHLON MEDICAL INC /s/ James B. Frakes James B. Frakes Chief Financial Officer 2020-01-24